Insulin, glibenclamide or metformin treatment for non insulin dependent diabetes: heterogenous responses of standard measures of insulin action and insulin secretion before and after differing hypoglycaemic therapy.
Using carefully selected relatively non-obese non insulin dependent diabetic patients, we were not able to show differences in standard measures of insulin production or insulin action between patients treated with a long acting crystalline zinc insulin, with glibenclamide, or with metformin for a six week period. All three drugs were hypoglycaemic, but a fall in basal hepatic glucose output measured by the 3H3 glucose technique was only seen in those patients who had an initial fasting plasma glucose above 12.0 mmol/l, irrespective of treatment.
Boyd
K
K
Sir George E Clark Metabolic Unit, Royal Victoria Hospital, Belfast, UK.
Rogers
C
C
Boreham
C
C
Andrews
W J
WJ
Hadden
D R
DR
D001786:Blood Glucose / Q000378:metabolism; D015992:Body Mass Index; D002096:C-Peptide / Q000097:blood; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D015309:Glucose Clamp Technique; D005905:Glyburide / Q000627:therapeutic use*; D006442:Glycated Hemoglobin / Q000032:analysis; D006029:Glycosuria; D006801:Humans; D007328:Insulin / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*; D007333:Insulin Resistance; D000078790:Insulin Secretion; D008657:Metabolic Clearance Rate; D008687:Metformin / Q000627:therapeutic use*; D008875:Middle Aged; D011865:Radioisotope Dilution Technique; D014316:Tritium
D001786:Blood Glucose; D002096:C-Peptide; D005905:Glyburide; D006442:Glycated Hemoglobin; D007328:Insulin; D008687:Metformin; D014316:Tritium